Navigation Links
Oncolytics Biotech(R) Inc. Research Collaborators Present Glioma Reovirus Research at ASV Annual Meeting
Date:7/15/2009

CALGARY, July 15 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that a poster presentation by Dr. Jacqueline Parker et al. entitled "Anti-Tumor Activity of Reovirus is Synergistically Enhanced in Combination with Temozolomide and Low Dose Irradiation in Primary Patient Glioma Xenografts Resistant to Treatment with Either Therapy Alone" was made yesterday at the 28th American Society for Virology (ASV) Annual Meeting. The meeting is being held in Vancouver, British Columbia, from July 11-15, 2009.

"These results support the strategic direction we're taking with the REOLYSIN(R) clinical program," said Dr. Matt Coffey, Chief Operating Officer for Oncolytics. "The future program for REOLYSIN, including our pivotal program, is focused on exploiting these underlying drug synergies."

The poster covers preclinical work using reovirus in combination with low dose irradiation (IR) and temozolomide (TMZ). A panel of glioma cell lines and primary patient glioma explant cells were tested for susceptibility to reovirus, IR, TMZ, or a combination of these therapies in vitro. The combination index analyses revealed moderate to strong synergy in primary patient glioma cells treated with reovirus plus IR and TMZ in vitro. This effect was also seen in vivo in flank tumor xenografts from primary patient tumors resistant to reovirus therapy alone.

The investigators concluded that the data supports the use of reovirus in combination with standard radiation and chemotherapies for the treatment of malignant glioma in humans.

The poster will be available on the Oncolytics website at www.oncolyticsbiotech.com at a later date.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the de
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Oncolytics Biotech(R) Inc. Completes Patient Enrolment in U.K. Combination REOLYSIN(R) and Paclitaxel/Carboplatin Head and Neck Cancer Trial
2. Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at ASCO Annual Meeting
3. Oncolytics Biotech(R) Inc.s Research Collaborators to Present Data on REOLYSIN(R) Clinical Trials at ASCO Conference
4. Oncolytics(R) Biotech Inc. Completes Patient Enrolment in U.S. Phase 2 Sarcoma Study
5. Oncolytics Biotech(R) Inc. Announces 2009 First Quarter Results
6. Oncolytics Biotech(R) Inc. Announces Details of 2009 Annual Shareholder Meeting
7. Media Advisory - Oncolytics Biotech(R) Inc. to Present at BioFinance 2009
8. Oncolytics Biotech(R) Inc. Announces Positive Results of U.K. Phase II REOLYSIN(R) and Radiation Combination Clinical Trial
9. Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial
10. Oncolytics Biotech(R) Inc. Collaborators Present Reovirus Research at Replicating Oncolytic Virus Meeting
11. Oncolytics Biotech(R) Inc. Collaborators Present Positive Head and Neck Results in Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... Calif. , May 17, 2013  Cellular ... has achieved 50% enrollment of the total projected ... evaluate the safety and preliminary efficacy of the ... therapy for Knee Osteoarthritis (KOA). To date the ... reported. The Phase I open label ...
(Date:5/17/2013)... -- Insero Health, Inc., a company developing natural compounds to ... disorders, is today reporting top-line results from a Phase ... with drug-resistant epilepsy.  The data are being presented at ... by Dr. Steven Schachter , Harvard ... Board.  In this study, INS001 appeared safe and well ...
(Date:5/17/2013)... May 17, 2013 RURO Inc. ... version 4.1, a versatile refinement to the smart ... solution, improves its advanced methodical management for transgenic ... ezColony 4.1. The network-based platform provides user access ... research. While continuing to emphasize streamlined tasks, such ...
(Date:5/17/2013)... Darrington, WA (PRWEB) May 17, 2013 Tooth ... 5th graders showing active signs of the disease. The World ... children and nearly 100% of adults have cavities. What are ... Research is showing a strong connection between the oral ... why is this disease so rampant, yet it is also ...
Breaking Biology Technology:Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2Insero Health Reports Positive Data on Phase I Trial of Novel Therapy for Drug-resistant Epilepsy 2RURO Introduces ezColony 4.1 – The Versatile Transgenic Animal Colony Management Software 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 3
... , , , WHAT: News conference ... for the Warsaw/Kosciusko County community, WHEN: Wednesday, Sept. 23 at ... 200 Seminary Drive Winona Lake, Ind., ... Brad Bishop, Board President, Kosciusko County Community, ...
... SAN FRANCISCO, Sept. 22 A symposium was held last ... Austria entitled "Beta-blockers may now be beneficial in asthma and ... far Inverseon,s asthma program has advanced in the past couple ... and evidence is accumulating that INV102 is showing pre-clinical activity ...
... , DEERFIELD, Ill., Sept. 22 ... annual Astellas Transplant Scholars Awards , $5,000 educational scholarships awarded ... about how transplant affected their education plans, and how they would ... further education and giving back to the transplant community. , ...
Cached Biology Technology:INV102 Asthma Product Discussed at the European Respiratory Society 2Astellas Awards Educational Scholarships to Six Transplant Recipients Who Embody the Spirit of Giving Back 2Astellas Awards Educational Scholarships to Six Transplant Recipients Who Embody the Spirit of Giving Back 3Astellas Awards Educational Scholarships to Six Transplant Recipients Who Embody the Spirit of Giving Back 4
(Date:5/18/2013)... An increasing number of U.S. children are experiencing ... to research presented at Digestive Disease Week (DDW). ... at the Cleveland Clinic Children,s Hospital found that ... breath compared to their lean counterparts. The pattern ... can be correlated to potential complications associated with ...
(Date:5/17/2013)... residents of all ages will celebrate the science ... on our daily lives during the inaugural Atlanta ... and educators from local museums, corporations, K-12 schools ... 40 different events for children and adults at ... http://atlantasciencefestival.org . , The annual Atlanta Science ...
(Date:5/17/2013)... College study finds human-caused climate change may have ... contradicting a host of recent studies that predict ... , The findings, which appear in the journal ... for survival of a creature thought to be ... tropical cold-blooded animals, especially forest lizards, will be ...
Breaking Biology News(10 mins):New research identifies risks, interventions for children's GI health 2New research identifies risks, interventions for children's GI health 3First Atlanta Science Festival set for 2014 2Climate change may have little impact on tropical lizards 2
... will take the lead with three other federal ... Initiative (NRI) and released a solicitation for proposals ... Manufacturing Initiative and technology transfer efforts and supports ... United States that work beside, or cooperatively, with ...
... confirms that a variant on the patatin-like phospholipase-3 (PNPLA3) ... patients with chronic hepatitis C virus (HCV). The PNPLA3 ... important genetic predictor and potential therapeutic target in chronic ... July issue of Hepatology , a peer-reviewed journal ...
... Johns Hopkins University graduate students have invented a device to ... blood vessels in patients who need blood-cleansing dialysis because of ... the skin in a patient,s leg, would give a technician ... opened and closed at the beginning and end of a ...
Cached Biology News:NSF leads interagency collaboration to develop advanced robotics 2NSF leads interagency collaboration to develop advanced robotics 3NSF leads interagency collaboration to develop advanced robotics 4Gene variant increases fatty liver risk and fibrosis progression 2Student team invents device to cut dialysis risk 2
Mouse monoclonal [CAT-1] to Chloramphenicol Acetyltransferase ( Abpromise for all tested applications)....
... MaV203 Competent Yeast Cells are designed for ... 1). S. cerevisiae strain MaV203 contains deletions ... for use with GAL4-based two-hybrid systems. The ... for selection of ProQuest bait and prey ...
mCD-1 10 transcription reactions...
Request Info...
Biology Products: